Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Hypoadiponectinemia in Patients With Paroxysmal Atrial Fibrillation

  • Choi, Byung Joo (Division of Cardiology, Department of Internal Medicine, Kosin University School of Medicine) ;
  • Heo, Jung Ho (Division of Cardiology, Department of Internal Medicine, Kosin University School of Medicine) ;
  • Choi, In-Soo (Division of Cardiology, Department of Internal Medicine, Kosin University School of Medicine) ;
  • Lee, Si-Won (Division of Cardiology, Department of Internal Medicine, Kosin University School of Medicine) ;
  • Kim, Hyun-Soo (Division of Cardiology, Department of Internal Medicine, Kosin University School of Medicine) ;
  • Lee, Jae Woo (Division of Cardiology, Department of Internal Medicine, Kosin University School of Medicine) ;
  • Cha, Tae-Joon (Division of Cardiology, Department of Internal Medicine, Kosin University School of Medicine)
  • Published : 2012.10.31
⟨ Previous Next ⟩

Abstract

Background and Objectives: Adiponectin is an adipose tissue-derived hormone that has beneficial effects on cardiac function and has been reported to be associated with lipid metabolism, glucose metabolism, and insulin resistance. Serum levels of adiponectin are reduced in obese individuals compared with non-obese individuals. Obesity is associated with an increased incidence of atrial fibrillation (AF); however, the role of adiponectin in AF is unclear. The aim of this study is to evaluate the relationship between the plasma adiponectin level and AF. Subjects and Methods: Sixty-one consecutive patients were prospectively enrolled for this study. Subjects were divided into two groups: patients with AF (n=30) and controls (n=31). Laboratory evaluation, including levels of plasma adiponectin, was performed and echocardiographic parameters were measured. Results: The baseline characteristics were not different between the two groups. The plasma adiponectin level of patients in the AF group was significantly lower than in the control group $(14.9{\pm}7.2\;vs.\;19.{\pm}8.9\;{\mu}g/mL,\;p<0.05)$. In addition, when we divided the AF patients into paroxysmal and chronic AF, the plasma adiponectin level was significantly lower in patients with paroxysmal AF, compared with the control group. In multiple binary logistic regression analysis to evaluate the independent predictors for AF, adiponectin and left atrial diameter were strong independent predictors of AF. Conclusion: In this study a lower plasma adiponectin concentration was significantly associated with that of paroxysmal AF. Hypoadiponectinemia can potentially be an important risk factor for AF.

Keywords

References

  1. Goette A, Arndt M, Röcken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101:2678-81. https://doi.org/10.1161/01.CIR.101.23.2678
  2. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91. https://doi.org/10.1161/hc4901.101760
  3. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92. https://doi.org/10.1093/eurheartj/ehi350
  4. Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 2009;11:1032-6. https://doi.org/10.1093/europace/eup103
  5. Nicolaou VN, Papadakis JE, Karatzis EN, Dermitzaki SI, Tsakiris AK, Skoufas PD. Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. Angiology 2007;58:21-5. https://doi.org/10.1177/0003319706297913
  6. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007;116(11 Suppl):I213-9.
  7. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007;49:531-8. https://doi.org/10.1016/j.jacc.2006.08.061
  8. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Aatrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-50.
  9. McNamara RL, Brass LM, Drozda JP Jr, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Commitee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol 2004;44:475-95. https://doi.org/10.1016/j.jacc.2004.06.041
  10. Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/ SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance: endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Soc Echocardiogr 2007;20:787-805. https://doi.org/10.1016/j.echo.2007.06.011
  11. Celik T, Iyisoy A. A new villain of the village: hypoadiponectinemia. Int J Cardiol 2009;137:54-5. https://doi.org/10.1016/j.ijcard.2008.04.088
  12. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62. https://doi.org/10.1161/CIRCULATIONAHA.104.530972
  13. George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006;92:1420-4. https://doi.org/10.1136/hrt.2005.083345
  14. McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007;28:829-35. https://doi.org/10.1093/eurheartj/ehm033
  15. Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007;28:1723-30. https://doi.org/10.1093/eurheartj/ehm154
  16. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-41.
  17. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129-34. https://doi.org/10.1093/ndt/gfh568
  18. Shimano M, Shibata R, Tsuji Y, et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 2008;72:1120-4. https://doi.org/10.1253/circj.72.1120
  19. Rienstra M, Sun JX, Lubitz SA, et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J 2012;163:119-24. https://doi.org/10.1016/j.ahj.2011.09.029
  20. Kumagai K. Upstream approach for atrial fibrillation. Nihon Yakurigaku Zasshi 2010;135:59-61. https://doi.org/10.1254/fpj.135.59
  21. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81. https://doi.org/10.1161/01.HYP.0000078490.59735.6E
  22. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-7. https://doi.org/10.1161/01.HYP.35.6.1270
  23. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009;24:1876-83. https://doi.org/10.1093/ndt/gfn770
  24. Yenicesu M, Yilmaz MI, Caglar K, et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005;99:c115-21. https://doi.org/10.1159/000083929
  25. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-7. https://doi.org/10.1016/j.jacc.2009.02.038
  26. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13. https://doi.org/10.1056/NEJMoa020245
  27. Della Mea P, Lupia M, Bandolin V, et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005;18:30-5. https://doi.org/10.1016/j.amjhyper.2004.08.029
  28. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9. https://doi.org/10.1161/01.ATV.20.6.1595
  29. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-9. https://doi.org/10.1161/01.ATV.0000048856.22331.50
  30. Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000;35:1256-62. https://doi.org/10.1016/S0735-1097(00)00515-5

Cited by

  1. Total Adiponectin Is Inversely Associated with Platelet Activation and CHA 2 DS 2 -VASc Score in Anticoagulated Patients with Atrial Fibrillation vol.2014, pp.None, 2012, https://doi.org/10.1155/2014/908901
  2. The associations of leptin, adiponectin and resistin with incident atrial fibrillation in women vol.102, pp.17, 2016, https://doi.org/10.1136/heartjnl-2015-308927
  3. Effect of fish oil on circulating asymmetric dimethylarginine and adiponectin in overweight or obese patients with atrial fibrillation vol.8, pp.4, 2012, https://doi.org/10.1002/fsn3.1518
  4. Association between Serum Adiponectin and Atrial Fibrillation: A Case-Control Study Stratified by Age and Gender vol.2021, pp.None, 2012, https://doi.org/10.1155/2021/6633948